Sunday, 22 November 2026 X LinkedIn Bluesky RSS Send us news
LungDaily The Pulse of Respiratory Health
Voices

Stephen V Liu: No clear standard for NSCLC transformed to SCLC, despite high DLL3

Liu said a talk at MaTOSLung highlighted disappointing tarlatamab outcomes in transformed disease, despite high DLL3 expression, and welcomed ongoing studies in this population.

“no clear standard exists and huge unmet need”— Stephen V Liu, MD

Stephen V Liu, a thoracic oncologist, wrote on X on 21 November 2026 about a talk on non-small cell lung cancer (NSCLC) that has transformed to small cell lung cancer (SCLC). The talk was given at MaTOSLung by a speaker who posts as @drshieldsmd. Liu described it as a "great talk" on how to approach this setting.

According to Liu, transformed disease shows high expression of DLL3, but outcomes with tarlatamab have been disappointing.

Liu said he was pleased to see ongoing studies in this population. He wrote that no clear standard exists for these patients and that the unmet need is large.

Liu's X profile lists him as chief of haematology and oncology at Georgetown and MedStar Georgetown University Hospital, and head of developmental therapeutics at Lombardi Cancer Center.

Original source

#lung-cancer#therapeutics#trial

Related stories

More in Voices

See all

LungDaily reports on public posts, papers and news from the lung health community. This article is based on the source linked above and was produced with AI-assisted tools under our editorial standards; facts and quotes are checked against the original before publication. Featured here, or spotted an error? Request a correction or removal.